1. |
Alteplase in acute ischaemic stroke: more evidence needed |
|
Inpharma Weekly,
Volume &NA;,
Issue 1373,
2003,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
2. |
A new US FDA guidance requires pharmaceutical companies to integrate race and ethnicity data |
|
Inpharma Weekly,
Volume &NA;,
Issue 1373,
2003,
Page 3-3
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
3. |
Recommendations for the vaccination of US prison inmates against hepatitis viruses have been released by the US CDC.* |
|
Inpharma Weekly,
Volume &NA;,
Issue 1373,
2003,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
4. |
Dimethyl sulfoxide preferred in reflex sympathetic dystrophy |
|
Inpharma Weekly,
Volume &NA;,
Issue 1373,
2003,
Page 5-5
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
5. |
Fluorouracil plus eniluracil maintains QOL in colorectal cancer |
|
Inpharma Weekly,
Volume &NA;,
Issue 1373,
2003,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
6. |
Pexelizumab: reduced mortality rate after acute MI |
|
Inpharma Weekly,
Volume &NA;,
Issue 1373,
2003,
Page 7-8
RM Poole,
Preview
|
|
摘要:
The novel complement inhibitor pexelizumab reduced the mortality rate in patients receiving adjunct therapy following acute myocardial infarction (MI) in preliminary results from the CARDINAL (Complement And ReDuction of INfarct size after Angioplasty or Lytics) programme presented at the 75th Annual Scientific Sessions of the American Heart Association (AHA) [Chicago, US; November 2002]. The CARDINAL programme consists of two studies, COMMA and COMPLY, that were designed to evaluate the effects of pexelizumab in patients with acute MI receiving percutaneous transluminal coronary angioplasty (PTCA), and thrombolytics, respectively. Although neither study achieved the primary endpoint of a reduction in infarct size at 72 hours, a significant 70% reduction in the incidence of all-cause mortality was observed in pexelizumab, compared with placebo, recipients in the COMMA study. This is the first clinical trial in approximately 10 years in which an adjunct to reperfusion therapy has demonstrated a reduction in mortality.
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
7. |
Rasagiline monotherapy beneficial in early Parkinson's disease |
|
Inpharma Weekly,
Volume &NA;,
Issue 1373,
2003,
Page 8-8
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
8. |
PT-141*is effective in the treatment of patients with moderate-to-severe male erectile dysfunction |
|
Inpharma Weekly,
Volume &NA;,
Issue 1373,
2003,
Page 9-9
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
9. |
Novel DNA vaccine inhibits tumour growth |
|
Inpharma Weekly,
Volume &NA;,
Issue 1373,
2003,
Page 10-10
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
10. |
Salmeterol + fluticasone: positive results in COPD |
|
Inpharma Weekly,
Volume &NA;,
Issue 1373,
2003,
Page 11-11
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|